If you made any changes in Pure, your changes will be visible here soon.

Research Output 1982 2019

2019

Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer

Formisano, L., Lu, Y., Servetto, A., Hanker, A. B., Jansen, V. M., Bauer, J. A., Sudhan, D. R., Guerrero-Zotano, A. L., Croessmann, S., Guo, Y., Ericsson, P. G., Lee, K. M., Nixon, M. J., Schwarz, L. J., Sanders, M. E., Dugger, T. C., Cruz, M. R., Behdad, A., Cristofanilli, M., Bardia, A. & 11 others, O’Shaughnessy, J., Nagy, R. J., Lanman, R. B., Solovieff, N., He, W., Miller, M., Su, F., Shyr, Y., Mayer, I. A., Balko, J. M. & Arteaga, C. L., Dec 1 2019, In : Nature communications. 10, 1, 1373.

Research output: Contribution to journalArticle

Open Access
breast
inhibitors
cancer
Breast Neoplasms
Protein-Tyrosine Kinases
3 Citations (Scopus)

A phase II randomized study of neoadjuvant letrozole plus alpelisib for hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (NeO-ORB)

Mayer, I. A., Prat, A., Egle, D., Blau, S., Alejandro Perez Fidalgo, J., Gnant, M., Fasching, P. A., Colleoni, M., Wolff, A. C., Winer, E. P., Singer, C. F., Hurvitz, S., Estevez, L. G., Van Dam, P. A., Kummel, S., Mundhenke, C., Holmes, F., Babbar, N., Charbonnier, L., Diaz-Padilla, I. & 3 others, Vogl, F. D., Sellami, D. & Arteaga, C. L., Jan 1 2019, In : Clinical Cancer Research. 25, 10, p. 2975-2987 13 p.

Research output: Contribution to journalArticle

Open Access
letrozole
Hormones
Breast Neoplasms
Placebos
Exanthema

Author Correction: Drug response in organoids generated from frozen primary tumor tissues (Scientific Reports, (2016), 6, 1, (18889), 10.1038/srep18889)

Walsh, A. J., Cook, R. S., Sanders, M. E., Arteaga, C. L. & Skala, M. C., Dec 1 2019, In : Scientific Reports. 9, 1, 6517.

Research output: Contribution to journalComment/debate

Open Access
Organoids
Pharmaceutical Preparations
Neoplasms
2 Citations (Scopus)

Author Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancers (Nature, (2018), 554, 7691, (189-194), 10.1038/nature25475)

Hyman, D. M., Piha-Paul, S. A., Won, H., Rodon, J., Saura, C., Shapiro, G. I., Juric, D., Quinn, D. I., Moreno, V., Doger, B., Mayer, I. A., Boni, V., Calvo, E., Loi, S., Lockhart, A. C., Erinjeri, J. P., Scaltriti, M., Ulaner, G. A., Patel, J., Tang, J. & 27 others, Beer, H., Selcuklu, S. D., Hanrahan, A. J., Bouvier, N., Melcer, M., Murali, R., Schram, A. M., Smyth, L. M., Jhaveri, K., Li, B. T., Drilon, A., Harding, J. J., Iyer, G., Taylor, B. S., Berger, M. F., Cutler, R. E., Xu, F., Butturini, A., Eli, L. D., Mann, G., Farrell, C., Lalani, A. S., Bryce, R. P., Arteaga, C. L., Meric-Bernstam, F., Baselga, J. & Solit, D. B., Feb 28 2019, In : Nature. 566, 7745, p. E11-E12

Research output: Contribution to journalComment/debate

Open Access
Phosphotransferases
Neoplasms
2 Citations (Scopus)

Challenges for the Clinical Development of PI3K Inhibitors: Strategies to Improve Their Impact in Solid Tumors

Hanker, A. B., Kaklamani, V. & Arteaga, C. L., Apr 1 2019, In : Cancer discovery. 9, 4, p. 482-491 10 p.

Research output: Contribution to journalReview article

Phosphatidylinositol 3-Kinases
Neoplasms
Drug-Related Side Effects and Adverse Reactions
Patient Selection
Cell Survival
3 Citations (Scopus)

Combined blockade of activating ERBB2 mutations and ER results in synthetic lethality of ERþ/HER2 mutant breast cancer

Croessmann, S., Formisano, L., Kinch, L. N., Gonzalez-Ericsson, P. I., Sudhan, D. R., Nagy, R. J., Mathew, A., Bernicker, E. H., Cristofanilli, M., He, J., Cutler, R. E., Lalani, A. S., Miller, V. A., Lanman, R. B., Grishin, N. V. & Arteaga, C. L., Jan 1 2019, In : Clinical Cancer Research. 25, 1, p. 277-289 13 p.

Research output: Contribution to journalArticle

Estradiol Congeners
Estrogen Receptors
Breast Neoplasms
Mutation
MCF-7 Cells

Correction: ER+ breast cancers resistant to prolonged neoadjuvant letrozole exhibit an E2F4 transcriptional program sensitive to CDK4/6 inhibitors (Clinical Cancer Research (2018) 24 (2517–29) DOI: 10.1158/1078-0432.CCR-17-2904)

Guerrero-Zotano, A. L., Stricker, T. P., Formisano, L., Hutchinson, K. E., Stover, D. G., Lee, K. M., Schwarz, L. J., Giltnane, J. M., Estrada, M. V., Jansen, V. M., Servetto, A., Gavila, J. J., Perez-Fidalgo, A., Lluch, A., Llombart-Cussac, A., Bayar, M. A., Michiels, S., Andre, F., Arnedos, M., Guillem, V. & 2 others, Ruiz-Simon, A. & Arteaga, C. L., Feb 15 2019, In : Clinical Cancer Research. 25, 4, 1 p.

Research output: Contribution to journalComment/debate

Open Access
letrozole
Disclosure
Emotions
Breast Neoplasms
Research
Open Access
Disclosure
Emotions
Breast Neoplasms
Neoplasms
N-(4-(3-chloro-4-(2-pyridinylmethoxy)anilino)-3-cyano-7-ethoxy-6-quinolyl)-4-(dimethylamino)-2-butenamide

Correction: Treatment of triple-negative breast cancer with TORC1/2 inhibitors sustains a drug-resistant and Notch-dependent cancer stem cell population (Cancer Research (2016) 76 (440–452) DOI: 10.1158/0008-5472.CAN-15-1640-T)

Bhola, N. E., Jansen, V. M., Koch, J. P., Li, H., Formisano, L., Williams, J. A., Grandis, J. R. & Arteaga, C. L., Feb 15 2019, In : Cancer Research. 79, 4, 1 p.

Research output: Contribution to journalComment/debate

Triple Negative Breast Neoplasms
Neoplastic Stem Cells
Disclosure
Emotions
Research

Correction: Pik3ca c2 domain deletions hyperactivate phosphoinositide 3-kinase (pi3k), generate oncogene dependence, and are exquisitely sensitive to pi3ka inhibitors(Clin Cancer Res (2018) 24 (1426–35)DOI: 10.1158/1078-0432.CCR-17-2141)

Croessmann, S., Sheehan, J. H., Lee, K. M., Sliwoski, G., He, J., Nagy, R., Riddle, D., Mayer, I. A., Balko, J. M., Lanman, R., Miller, V. A., Cantley, L. C., Meiler, J. & Arteaga, C. L., Feb 15 2019, In : Clinical Cancer Research. 25, 4, 1 p.

Research output: Contribution to journalComment/debate

Open Access
1-Phosphatidylinositol 4-Kinase
Disclosure
Oncogenes
Emotions
Neoplasms

Correction: Extracellular matrix/integrin signaling promotes resistance to combined inhibition of HER2 and PI3K in HER2 þ breast cancer (Cancer Research (2017) 77 (3280–3292) DOI: 10.1158/0008-5472.CAN-16-2808)

Hanker, A. B., Estrada, M. V., Bianchini, G., Moore, P. D., Zhao, J., Cheng, F., Koch, J. P., Gianni, L., Tyson, D. R., Sánchez, V., Rexer, B. N., Sanders, M. E., Zhao, Z., Stricker, T. P. & Arteaga, C. L., Feb 15 2019, In : Cancer Research. 79, 4, 1 p.

Research output: Contribution to journalComment/debate

Open Access
Disclosure
Phosphatidylinositol 3-Kinases
Integrins
Extracellular Matrix
Emotions

Correction: Kinome-wide functional screen identifies role of PLK1 in hormone-independent, ER-positive breast cancer (Cancer Research (2015) 75 (405–414) DOI: 10.1158/0008-5472.CAN-14-2475)

Bhola, N. E., Jansen, V. M., Bafna, S., Giltnane, J. M., Balko, J. M., Estrada, M. V., Meszoely, I., Mayer, I., Abramson, V., Ye, F., Sanders, M., Dugger, T. C., Allen, E. V. & Arteaga, C. L., Feb 15 2019, In : Cancer Research. 79, 4, 1 p.

Research output: Contribution to journalComment/debate

Open Access
Disclosure
Emotions
Hormones
Breast Neoplasms
Research

Correction: Association of FGFR1 with ERA maintains ligand-independent ER transcription and mediates resistance to estrogen deprivation in ER þ breast cancer (Clinical Cancer Research (2019)23 (6138–6150) Doi:10.1158/1078-0432.CCR-17-1232)

Formisano, L., Stauffer, K. M., Young, C. D., Bhola, N. E., Angel, L. G. Z., Jansen, V. M., Estrada, M. M., Hutchinson, K. E., Giltnane, J. M., Schwarz, L. J., Lu, Y., Balko, J. M., Deas, O., Cairo, S., Judde, J. G., Mayer, I. A., Sanders, M., Dugger, T. C., Bianco, R., Stricker, T. & 1 others, Arteaga, C. L., Feb 15 2019, In : Clinical Cancer Research. 25, 4, 1 p.

Research output: Contribution to journalComment/debate

Open Access
Disclosure
Emotions
Estrogens
Breast Neoplasms
Ligands

Correction: HER2-overexpressing breast cancers amplify FGFR signaling upon acquisition of resistance to dual therapeutic blockade of HER2(Clin Cancer Res. (2017) 23:15 (4323-4334) DOI: 10.1158/1078-0432.CCR-16-2287)

Hanker, A. B., Garrett, J. T., Valeria Estrada, M., Moore, P. D., Ericsson, P. G., Koch, J. P., Langley, E., Singh, S., Kim, P. S., Frampton, G. M., Sanford, E., Owens, P., Becker, J., Groseclose, M. R., Castellino, S., Joensuu, H., Huober, J., Brase, J. C., Majjaj, S., Brohee, S. & 6 others, Venet, D., Brown, D., Baselga, J., Piccart, M., Sotiriou, C. & Arteaga, C. L., Feb 15 2019, In : Clinical Cancer Research. 25, 4, 1 p.

Research output: Contribution to journalComment/debate

Open Access
Disclosure
Emotions
Breast Neoplasms
Neoplasms
Therapeutics

Correction: RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: Therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors(Clin Cancer Res. (2016)22:6 (1499-509) DOI: 10.1158/1078-0432.CCR-15-1125)

Loi, S., Dushyanthen, S., Beavis, P. A., Salgado, R., Denkert, C., Savas, P., Combs, S., Rimm, D. L., Giltnane, J. M., Estrada, M. V., Sanchez, V., Sanders, M. E., Cook, R. S., Pilkinton, M. A., Mallal, S. A., Wang, K., Miller, V. A., Stephens, P. J., Yelensky, R., Doimi, F. D. & 5 others, Gomez, H., Ryzhov, S. V., Darcy, P. K., Arteaga, C. L. & Balko, J. M., Feb 15 2019, In : Clinical Cancer Research. 25, 4, 1 p.

Research output: Contribution to journalComment/debate

Open Access
Triple Negative Breast Neoplasms
Tumor-Infiltrating Lymphocytes
Mitogen-Activated Protein Kinase Kinases
Disclosure
Emotions
Open Access
Disclosure
Emotions
Research
Neoplasms

Correction: 18 F-fluoroestradiol PET/CT measurement of estrogen receptor suppression during a phase I trial of the novel estrogen receptor-targeted therapeutic GDC-0810: Using an imaging biomarker to guide drug dosage in subsequent trials(Clin Cancer Res. (2017) 3:12 (3053-3060) DOI: 10.1158/1078-0432.CCR-16-219)

Wang, Y., Ayres, K. L., Goldman, D. A., Dickler, M. N., Bardia, A., Mayer, I. A., Winer, E., Fredrickson, J., Arteaga, C. L., Baselga, J., Manning, H. C., Mahmood, U. & Ulaner, G. A., Feb 15 2019, In : Clinical Cancer Research. 25, 4, 1 p.

Research output: Contribution to journalComment/debate

Open Access
Disclosure
Estrogen Receptors
Emotions
Biomarkers
Pharmaceutical Preparations

Correction to: Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer (Clinical Drug Investigation, (2018), 38, 11, (1071-1075), 10.1007/s40261-018-0696-3)

Hoste, G., Slembrouck, L., Jongen, L., Punie, K., Matton, T., Vander Borght, S., Vanden Bempt, I., Menten, J., Wildiers, H., Floris, G., Arteaga, C. L. & Neven, P., Jan 1 2019, (Accepted/In press) In : Clinical Drug Investigation.

Research output: Contribution to journalArticle

Consultants
Breast Neoplasms
Pharmaceutical Preparations
fulvestrant
1 Citation (Scopus)

Discovery of Potent Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors That Demonstrate in Vivo Activity in Mouse Xenograft Models of Human Cancer

Lee, T., Christov, P. P., Shaw, S., Tarr, J. C., Zhao, B., Veerasamy, N., Jeon, K. O., Mills, J. J., Bian, Z., Sensintaffar, J. L., Arnold, A. L., Fogarty, S. A., Perry, E., Ramsey, H. E., Cook, R. S., Hollingshead, M., Davis Millin, M., Lee, K. M., Koss, B., Budhraja, A. & 7 others, Opferman, J. T., Kim, K., Arteaga, C. L., Moore, W. J., Olejniczak, E. T., Savona, M. R. & Fesik, S. W., Apr 25 2019, In : Journal of Medicinal Chemistry. 62, 8, p. 3971-3988 18 p.

Research output: Contribution to journalArticle

Myeloid Leukemia
Myeloid Cells
Heterografts
Neoplasms
Triple Negative Breast Neoplasms

Erratum: Correction: The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer (eLife (2016) 5 PII: e44851)

Joseph, J. D., Darimont, B., Zhou, W., Arrazate, A., Young, A., Ingalla, E., Walter, K., Blake, R. A., Nonomiya, J., Guan, Z., Kategaya, L., Govek, S. P., Lai, A. G., Kahraman, M., Brigham, D., Sensintaffar, J., Lu, N., Shao, G., Qian, J., Grillot, K. & 26 others, Moon, M., Prudente, R., Bischoff, E., Lee, K. J., Bonnefous, C., Douglas, K. L., Julien, J. D., Nagasawa, J. Y., Aparicio, A., Kaufman, J., Haley, B., Giltnane, J. M., Wertz, I. E., Lackner, M. R., Nannini, M. A., Sampath, D., Schwarz, L., Manning, H. C., Tantawy, M. N., Arteaga, C. L., Heyman, R. A., Rix, P. J., Friedman, L., Smith, N. D., Metcalfe, C. & Hager, J. H., Jan 7 2019, In : eLife. 8

Research output: Contribution to journalComment/debate

Estrogen Receptors
Medicine
Breast Neoplasms
3-(4-(2-(2-chloro-4-fluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid

Erratum: Triple-negative breast cancers with amplication of JAK2 at the 9p24 locus demonstrate JAK2-specic dependence (Science Translational Medicine (2019) 11, 476, (eaaw6162), 10.1126/scitranslmed.aaw6162)

Balko, J. M., Schwarz, L. J., Luo, N., Estrada, M. V., Giltnane, J. M., Dávila-González, D., Wang, K., Sánchez, V., Dean, P. T., Combs, S. E., Hicks, D., Pinto, J. A., Landis, M. D., Doimi, F. D., Yelensky, R., Miller, V. A., Stephens, P. J., Rimm, D. L., Gómez, H., Chang, J. C. & 3 others, Sanders, M. E., Cook, R. S. & Arteaga, C. L., Jan 23 2019, In : Science Translational Medicine. 11, 476, eaaw6162.

Research output: Contribution to journalReview article

Triple Negative Breast Neoplasms
Translational Medical Research
Research

Erratum for the research article: Genomic proling of ER + breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance (Science Translational Medicine DOI: 10.1126/scitranslmed.aai7993)

Giltnane, J. M., Hutchinson, K. E., Stricker, T. P., Formisano, L., Young, C. D., Estrada, M. V., Nixon, M. J., Du, L., Sanchez, V., Ericsson, P. G., Kuba, M. G., Sanders, M. E., Mu, X. J., Van Allen, E. M., Wagle, N., Mayer, I. A., Abramson, V., Gόmez, H., Rizzo, M., Toy, W. & 15 others, Chandarlapaty, S., Mayer, E. L., Christiansen, J., Murphy, D., Fitzgerald, K., Wang, K., Ross, J. S., Miller, V. A., Stephens, P. J., Yelensky, R., Garraway, L., Shyr, Y., Meszoely, I., Balko, J. M. & Arteaga, C. L., Feb 13 2019, In : Science Translational Medicine. 11, 479, eaaw7620.

Research output: Contribution to journalComment/debate

Translational Medical Research
Estrogens
Breast Neoplasms
Research

Erratum for The research article: The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation (Science Translational Medicine DOI: 10.1126/scitranslmed.aal4682)

Kodack, D. P., Askoxylakis, V., Ferraro, G. B., Sheng, Q., Badeaux, M., Goel, S., Qi, X., Shankaraiah, R., Cao, Z. A., Ramjiawan, R. R., Bezwada, D., Patel, B., Song, Y., Costa, C., Naxerova, K., Wong, C. S. F., Kloepper, J., Das, R., Tam, A., Tanboon, J. & 13 others, Duda, D. G., Miller, C. R., Siegel, M. B., Anders, C. K., Sanders, M., Estrada, M. V., Schlegel, R., Arteaga, C. L., Brachtel, E., Huang, A., Fukumura, D., Engelman, J. A. & Jain, R. K., Jan 30 2019, In : Science Translational Medicine. 11, 477, aaw6935.

Research output: Contribution to journalComment/debate

Translational Medical Research
Phosphatidylinositol 3-Kinases
Breast Neoplasms
Brain
Research
1 Citation (Scopus)
1-Phosphatidylinositol 4-Kinase
Biomarkers
Hormones
Breast Neoplasms
Growth
2 Citations (Scopus)

Extended adjuvant therapy with neratinib plus fulvestrant blocks ER/HER2 crosstalk and maintains complete responses of ERþ/HER2þ breast cancers: Implications to the EXTENET trial

Sudhan, D. R., Schwarz, L. J., Guerrero-Zotano, A., Formisano, L., Nixon, M. J., Croessmann, S., Gonzalez Ericsson, P. I., Sanders, M., Balko, J. M., Avogadri-Connors, F., Cutler, R. E., Lalani, A. S., Bryce, R., Auerbach, A. & Arteaga, C. L., Jan 15 2019, In : Clinical Cancer Research. 25, 2, p. 771-783 13 p.

Research output: Contribution to journalArticle

Breast Neoplasms
Therapeutics
Cyclin D1
Gene Expression
fulvestrant
2018
5 Citations (Scopus)

Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2

Campone, M., Im, S. A., Iwata, H., Clemons, M., Ito, Y., Awada, A., Chia, S., Jagiełło-Gruszfeld, A., Pistilli, B., Tseng, L. M., Hurvitz, S., Masuda, N., Cortés, J., De Laurentiis, M., Arteaga, C. L., Jiang, Z., Jonat, W., Le Mouhaër, S., Sankaran, B., Bourdeau, L. & 3 others, El-Hashimy, M., Sellami, D. & Baselga, J., Nov 1 2018, In : European Journal of Cancer. 103, p. 147-154 8 p.

Research output: Contribution to journalArticle

Placebos
Phosphatidylinositol 3-Kinase
Hormones
Breast Neoplasms
Survival

Correction: Will PI3K pathway inhibitors be effective as single agents in patients with cancer? [Oncotarget. 2, (2011), 1314-1321]doi 10.18632/oncotarget.409

Garrett, J. T., Chakrabarty, A. & Arteaga, C. L., Aug 17 2018, In : Oncotarget. 9, 64, p. 32400 1 p.

Research output: Contribution to journalComment/debate

Proxy
Phosphatidylinositol 3-Kinases
Neoplasms

Correction: Kinome-wide RNA interference screen reveals a role for PDK1 in acquired resistance to CDK4/6 inhibition in ER-positive breast cancer (Cancer Research (2017) 77 (2488-2499) DOI: 10.1158/0008-5472)

Jansen, V. M., Bhola, N. E., Bauer, J. A., Formisano, L., Lee, K. M., Hutchinson, K. E., Witkiewicz, A., Moore, P. D., Estrada, M. V., Sánchez, V., Ericsson, P. G., Sanders, M. E., Pohlmann, P. R., Pishvaian, M. J., Riddle, D. A., Dugger, T. C., Wei, W., Knudsen, E. S. & Arteaga, C. L., Feb 15 2018, In : Cancer Research. 79, 4, 1 p.

Research output: Contribution to journalComment/debate

Disclosure
RNA Interference
Emotions
Breast Neoplasms
Research
5 Citations (Scopus)

ERþ Breast cancers resistant to prolonged neoadjuvant letrozole exhibit an e2f4 transcriptional program sensitive to cdk4/6 inhibitors

Guerrero-Zotano, A. L., Stricker, T. P., Formisano, L., Hutchinson, K. E., Stover, D. G., Lee, K. M., Schwarz, L. J., Giltnane, J. M., Estrada, M. V., Jansen, V. M., Servetto, A., Gavila, J., Alejandro, J. P. F., Lluch, A., Llombart-Cussac, A., Bayar, M. A., Michiels, S., Andre, F., Arnedos, M., Guillem, V. & 2 others, Ruiz-Simon, A. & Arteaga, C. L., Jun 1 2018, In : Clinical Cancer Research. 24, 11, p. 2517-2529 13 p.

Research output: Contribution to journalArticle

letrozole
Estrogens
Breast Neoplasms
Neoplasms
Genes
97 Citations (Scopus)

HER kinase inhibition in patients with HER2-and HER3-mutant cancers

Hyman, D. M., Piha-Paul, S. A., Won, H., Rodon, J., Saura, C., Shapiro, G. I., Juric, D., Quinn, D. I., Moreno, V., Doger, B., Mayer, I. A., Boni, V., Calvo, E., Loi, S., Lockhart, A. C., Erinjeri, J. P., Scaltriti, M., Ulaner, G. A., Patel, J., Tang, J. & 27 others, Beer, H., Duygu Selcuklu, S., Hanrahan, A. J., Bouvier, N., Melcer, M., Murali, R., Schram, A. M., Smyth, L. M., Jhaveri, K., Li, B. T., Drilon, A., Harding, J. J., Iyer, G., Taylor, B. S., Berger, M. F., Cutler, R. E., Xu, F., Butturini, A., Eli, L. D., Mann, G., Farrell, C., Lalani, A. S., Bryce, R. P., Arteaga, C. L., Meric-Bernstam, F., Baselga, J. & Solit, D. B., Feb 8 2018, In : Nature. 554, 7691, p. 189-194 6 p.

Research output: Contribution to journalArticle

Phosphotransferases
Mutation
Neoplasms
Biliary Tract Neoplasms
Missense Mutation
1 Citation (Scopus)

Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2

Luo, N., Formisano, L., Gonzalez-Ericsson, P. I., Sanchez, V., Dean, P. T., Opalenik, S. R., Sanders, M. E., Cook, R. S., Arteaga, C. L., Johnson, D. B. & Balko, J. M., Mar 5 2018, (Accepted/In press) In : OncoImmunology.

Research output: Contribution to journalArticle

Immunotherapy
Melanoma
Cell Death
Ligands
Programmed Cell Death 1 Receptor
1 Citation (Scopus)

Motivation for Launching a Cancer Metastasis Inhibition (CMI) Program

Pulley, J. M., Jerome, R. N., Ogletree, M. L., Bernard, G. R., Lavieri, R. R., Zaleski, N. M., Hong, C. C., Shirey-Rice, J. K., Arteaga, C. L., Mayer, I. A., Holroyd, K. J. & Cook, R. S., Feb 1 2018, In : Targeted Oncology. 13, 1, p. 61-68 8 p.

Research output: Contribution to journalArticle

Neoplasm Metastasis
Neoplasms
Circulating Neoplastic Cells
Single Nucleotide Polymorphism
Therapeutics
1 Citation (Scopus)

Neratinib: Inching up on the cure rate of HER2+ breast cancer?

Unni, N., Sudhan, D. R. & Arteaga, C. L., Aug 1 2018, In : Clinical Cancer Research. 24, 15, p. 3483-3485 3 p.

Research output: Contribution to journalArticle

Breast Neoplasms
Estrogen Receptors
Disease-Free Survival
Placebos
Neoplasms
4 Citations (Scopus)

PIK3CA C2 domain deletions hyperactivate phosphoinositide 3-kinase (PI3K), generate oncogene dependence, and are exquisitely sensitive to PI3Ka inhibitors

Croessmann, S., Sheehan, J. H., Lee, K. M., Sliwoski, G., He, J., Nagy, R., Riddle, D., Mayer, I. A., Balko, J. M., Lanman, R., Miller, V. A., Cantley, L. C., Meiler, J. & Arteaga, C. L., Mar 15 2018, In : Clinical Cancer Research. 24, 6, p. 1426-1435 10 p.

Research output: Contribution to journalArticle

1-Phosphatidylinositol 4-Kinase
Oncogenes
Phenotype
S 6
Structural Models
4 Citations (Scopus)

TGF-β signaling promotes tumor vasculature by enhancing the pericyte-endothelium association

Zonneville, J., Safina, A., Truskinovsky, A. M., Arteaga, C. L. & Bakin, A. V., Jun 19 2018, In : BMC Cancer. 18, 1, 670.

Research output: Contribution to journalArticle

Pericytes
Endothelium
Neoplasms
Fibronectins
Fibroblasts

The attenuation distribution across the long axis of breast cancer liver metastases at CT: A quantitative biomarker for predicting overall survival

Abramson, R. G., Lakomkin, N., Hainline, A., Kang, H., Hutson, M. S. & Arteaga, C. L., Jan 1 2018, In : American Journal of Roentgenology. 210, 1, p. W1-W7

Research output: Contribution to journalArticle

Liver Neoplasms
Biomarkers
Breast Neoplasms
Neoplasm Metastasis
Survival
2 Citations (Scopus)

Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer

Hoste, G., Slembrouck, L., Jongen, L., Punie, K., Matton, T., Vander Borght, S., Vanden Bempt, I., Menten, J., Wildiers, H., Floris, G., Arteaga, C. & Neven, P., Nov 1 2018, In : Clinical Drug Investigation. 38, 11, p. 1071-1075 5 p.

Research output: Contribution to journalArticle

Breast Neoplasms
Mutation
Neoplasm Genes
Therapeutics
fulvestrant
50 Citations (Scopus)

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer

Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y. S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Petrakova, K., Blackwell, K. L., Winer, E. P., Janni, W., Verma, S., Conte, P., Arteaga, C. L., Cameron, D. A., Mondal, S., Su, F., Miller, M., Elmeliegy, M., Germa, C. & 1 others, O'Shaughnessy, J., Jul 1 2018, In : Annals of Oncology. 29, 7, p. 1541-1547 7 p.

Research output: Contribution to journalArticle

letrozole
Placebos
Hormones
Breast Neoplasms
Confidence Intervals
2017
15 Citations (Scopus)

18F-fluoroestradiol PET/CT measurement of estrogen receptor suppression during a phase I trial of the novel estrogen receptor-targeted therapeutic GDC-0810: Using an imaging biomarker to guide drug dosage in subsequent trials

Wang, Y., Ayres, K. L., Goldman, D. A., Dickler, M. N., Bardia, A., Mayer, I. A., Winer, E., Fredrickson, J., Arteaga, C. L., Baselga, J., Manning, H. C., Mahmood, U. & Ulaner, G. A., Jun 15 2017, In : Clinical Cancer Research. 23, 12, p. 3053-3060 8 p.

Research output: Contribution to journalArticle

Estrogen Receptors
Biomarkers
Pharmaceutical Preparations
Down-Regulation
Tamoxifen
29 Citations (Scopus)

An acquired HER2T798I gatekeeper mutation induces resistance to neratinib in a patient with HER2 mutant-driven breast cancer

Hanker, A. B., Brewer, M. R., Sheehan, J. H., Koch, J. P., Sliwoski, G. R., Nagy, R., Lanman, R., Berger, M. F., Hyman, D. M., Solit, D. B., He, J., Miller, V., Cutler, R. E., Lalani, A. S., Cross, D., Lovly, C. M., Meiler, J. & Arteaga, C. L., Jan 1 2017, In : Cancer Discovery. 7, 6, p. 575-585 11 p.

Research output: Contribution to journalArticle

Breast Neoplasms
Mutation
Plasmacytoma
N-(4-(3-chloro-4-(2-pyridinylmethoxy)anilino)-3-cyano-7-ethoxy-6-quinolyl)-4-(dimethylamino)-2-butenamide
Isoleucine
6 Citations (Scopus)

An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression

Schwarz, L. J., Hutchinson, K. E., Rexer, B. N., Estrada, M. V., Gonzalez Ericsson, P. I., Sanders, M. E., Dugger, T. C., Formisano, L., Guerrero-Zotano, A., Red-Brewer, M., Young, C. D., Lantto, J., Pedersen, M. W., Kragh, M., Horak, I. D. & Arteaga, C. L., Nov 1 2017, In : Journal of the National Cancer Institute. 109, 11

Research output: Contribution to journalArticle

Neutralizing Antibodies
Neuregulin-1
Breast Neoplasms
Ligands
Pharmaceutical Preparations
92 Citations (Scopus)

A Phase Ib Study of Alpelisib (BYL719), a PI3Ka-Specific Inhibitor, with Letrozole in ERþ/HER2 Metastatic Breast Cancer

Mayer, I. A., Abramson, V. G., Formisano, L., Balko, J. M., Estrada, M. V., Sanders, M. E., Juric, D., Solit, D., Berger, M. F., Won, H. H., Li, Y., Cantley, L. C., Winer, E. & Arteaga, C. L., Jan 1 2017, In : Clinical Cancer Research. 23, 1, p. 26-34 9 p.

Research output: Contribution to journalArticle

letrozole
Breast Neoplasms
Neoplasms
Mutation
Maximum Tolerated Dose
22 Citations (Scopus)

A randomized phase II neoadjuvant study of cisplatin, paclitaxel with or without everolimus in patients with stage II/III triple-negative breast cancer (TNBC): Responses and long-term outcome correlated with increased frequency of DNA damage response gene mutations, TNBC subtype, AR status, and Ki67

Jovanovic, B., Mayer, I. A., Mayer, E. L., Abramson, V. G., Bardia, A., Sanders, M. E., Kuba, M. G., Estrada, M. V., Beeler, J. S., Shaver, T. M., Johnson, K. C., Sanchez, V., Rosenbluth, J. M., Dillon, P. M., Forero-Torres, A., Chang, J. C., Meszoely, I. M., Grau, A. M., Lehmann, B. D., Shyr, Y. & 4 others, Sheng, Q., Chen, S. C., Arteaga, C. L. & Pietenpol, J. A., Aug 1 2017, In : Clinical Cancer Research. 23, 15, p. 4035-4045 11 p.

Research output: Contribution to journalArticle

Triple Negative Breast Neoplasms
DNA Damage
Mutation
Arm
Genes
19 Citations (Scopus)

Association of FGFR1 with ERα maintains ligand-independent ER transcription and mediates resistance to estrogen deprivation in ER+ breast cancer

Formisano, L., Stauffer, K. M., Young, C. D., Bhola, N. E., Guerrero-Zotano, A. L., Jansen, V. M., Estrada, M. M., Hutchinson, K. E., Giltnane, J. M., Schwarz, L. J., Lu, Y., Balko, J. M., Deas, O., Cairo, S., Judde, J. G., Mayer, I. A., Sanders, M., Dugger, T. C., Bianco, R., Stricker, T. P. & 1 others, Arteaga, C. L., Oct 15 2017, In : Clinical Cancer Research. 23, 20, p. 6138-6151 14 p.

Research output: Contribution to journalArticle

letrozole
Estrogens
Breast Neoplasms
Ligands
RNA Sequence Analysis
124 Citations (Scopus)

Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Baselga, J., Im, S. A., Iwata, H., Cortés, J., De Laurentiis, M., Jiang, Z., Arteaga, C. L., Jonat, W., Clemons, M., Ito, Y., Awada, A., Chia, S., Jagiełło-Gruszfeld, A., Pistilli, B., Tseng, L. M., Hurvitz, S., Masuda, N., Takahashi, M., Vuylsteke, P., Hachemi, S. & 5 others, Dharan, B., Di Tomaso, E., Urban, P., Massacesi, C. & Campone, M., Jul 1 2017, In : The Lancet Oncology. 18, 7, p. 904-916 13 p.

Research output: Contribution to journalArticle

Phosphatidylinositol 3-Kinase
Placebos
Hormones
Breast Neoplasms
Disease-Free Survival
12 Citations (Scopus)

Extracellular matrix/integrin signaling promotes resistance to combined inhibition of HER2 and PI3K in HER2+ breast cancer

Hanker, A. B., Estrada, M. V., Bianchini, G., Moore, P. D., Zhao, J., Cheng, F., Koch, J. P., Gianni, L., Tyson, D. R., Sanchez, V., Rexer, B. N., Sánders, M. E., Zhao, Z., Stricker, T. P. & Arteaga, C. L., Jun 15 2017, In : Cancer Research. 77, 12, p. 3280-3292 13 p.

Research output: Contribution to journalArticle

Phosphatidylinositol 3-Kinases
Integrins
Extracellular Matrix
Collagen
Breast Neoplasms
8 Citations (Scopus)

Functional KRAS mutations and a potential role for PI3K/AKT activation in Wilms tumors

Polosukhina, D., Love, H. D., Correa, H., Su, Z., Dahlman, K. B., Pao, W., Moses, H. L., Arteaga, C. L., Lovvorn, H. N., Zent, R. & Clark, P. E., Apr 1 2017, In : Molecular Oncology. 11, 4, p. 405-421 17 p.

Research output: Contribution to journalArticle

Wilms Tumor
Phosphatidylinositol 3-Kinases
Catenins
Mutation
Disease Progression
16 Citations (Scopus)

Genomic profiling of ER+ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance

Giltnane, J. M., Hutchinson, K. E., Stricker, T. P., Formisano, L., Young, C. D., Estrada, M. V., Nixon, M. J., Du, L., Sanchez, V., Ericsson, P. G., Kuba, M. G., Sanders, M. E., Mu, X. J., Van Allen, E. M., Wagle, N., Mayer, I. A., Abramson, V., Gómez, H., Rizzo, M., Toy, W. & 15 others, Chandarlapaty, S., Mayer, E. L., Christiansen, J., Murphy, D., Fitzgerald, K., Wang, K., Ross, J. S., Miller, V. A., Stephens, P. J., Yelensky, R., Garraway, L., Shyr, Y., Meszoely, I., Balko, J. M. & Arteaga, C. L., Aug 9 2017, In : Science Translational Medicine. 9, 402, aai7993.

Research output: Contribution to journalArticle

letrozole
Estrogens
Breast Neoplasms
Estrogen Receptor Modulators
Neoplasms
12 Citations (Scopus)

HER2-overexpressing breast cancers amplify FGFR signaling upon acquisition of resistance to dual therapeutic blockade of HER2

Hanker, A. B., Garrett, J. T., Estrada, M. V., Moore, P. D., Ericsson, P. G., Koch, J. P., Langley, E., Singh, S., Kim, P. S., Frampton, G. M., Sanford, E., Owens, P., Becker, J., Groseclose, M. R., Castellino, S., Joensuu, H., Huober, J., Brase, J. C., Majjaj, S., Brohee, S. & 6 others, Venet, D., Brown, D., Baselga, J., Piccart, M., Sotiriou, C. & Arteaga, C. L., Aug 1 2017, In : Clinical Cancer Research. 23, 15, p. 4323-4334 12 p.

Research output: Contribution to journalArticle

Breast Neoplasms
Therapeutics
Drug Combinations
Heterografts
Trastuzumab
43 Citations (Scopus)

Kinome-wide RNA interference screen reveals a role for PDK1 in acquired resistance to CDK4/6 inhibition in ER-positive breast cancer

Jansen, V. M., Bhola, N. E., Bauer, J. A., Formisano, L., Lee, K. M., Hutchinson, K. E., Witkiewicz, A. K., Moore, P. D., Estrada, M. V., Sánchez, V., Ericsson, P. G., Sanders, M. E., Pohlmann, P. R., Pishvaian, M. J., Riddle, D. A., Dugger, T. C., Wei, W., Knudsen, E. S. & Arteaga, C. L., May 1 2017, In : Cancer Research. 77, 9, p. 2488-2499 12 p.

Research output: Contribution to journalArticle

Cyclin-Dependent Kinase 6
Cyclin-Dependent Kinase 4
RNA Interference
Protein Kinases
Breast Neoplasms